Decay-accelerating Factor Expression May Provide Immunoprotection Against Antibody-mediated Cardiac Allograft Rejection

Journal of Heart and Lung Transplantation

Volumn 27, Issue 4, 2008, Pages 357-361

  González Stawinski, Gonzalo V ^a   Tan, Carmela D ^a   Smedira, Nicholas G ^a   Starling, Randall C ^a   Rodríguez, E Rene ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; DECAY ACCELERATING FACTOR;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CASE REPORT; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; IMMUNITY; IMMUNOFLUORESCENCE TEST; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STAINING;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTIGENS, CD55; COLORING AGENTS; COMPLEMENT C3D; COMPLEMENT C4B; ENDOCARDIUM; EOSINE YELLOWISH-(YS); FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FLUORESCENT DYES; GRAFT REJECTION; HEART; HEART TRANSPLANTATION; HEMATOXYLIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PEPTIDE FRAGMENTS; PILOT PROJECTS; POSTOPERATIVE PERIOD; STAINING AND LABELING; TRANSPLANTATION, HOMOLOGOUS;

EID: 40949132494     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.01.008     Document Type: Article

References (23)

1. Hammond E.H., Yowell R.L., Price G.D., et al. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Lung Transplant 11 suppl (1992) S111-S119
2. Michaels P.J., Espejo M.L., Kobashigawa J., et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 22 (2003) 58-69
3. Kaczmarek I., Deutsch M.A., Sadoni S., et al. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant 26 (2007) 511-515
4. Lones M.A., Czer L.S., Trento A., et al. Clinical-pathologic features of humoral rejection in cardiac allografts: a study in 81 consecutive patients. J Heart Lung Transplant 14 (1995) 151-162
5. Takemoto S.K., Zeevi A., Feng S., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 4 (2004) 1033-1041
6. Byrne G.W., McCurry K.R., Martin M.J., et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 63 (1997) 149-155
7. Frank M., Reid K., Galli S., and Rajewsky K. The humoral immune response. 4th ed. (1999), Elsevier, London 635
8. Rodriguez E.R., Skojec D.V., Tan C.D., et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 5 (2005) 2778-2785
9. Reed E.F., Demetris A.J., Hammond E., et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 25 (2006) 153-159
10. Mason J.C., Lidington E.A., Yarwood H., Lublin D.M., and Haskard D.O. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum 44 (2001) 138-150
11. Mason J.C., Yarwood H., Sugars K., et al. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood 94 (1999) 1673-1682
12. Adams D.H., Kadner A., Chen R.H., and Farivar R.S. Human membrane cofactor protein (MCP, CD46) protects transgenic pig hearts from hyperacute rejection in primates. Xenotransplantation 8 (2001) 36-40
13. McCurry K.R., Kooyman D.L., Alvarado C.G., et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med 1 (1995) 423-427
14. Scoazec J.Y., Delautier D., Moreau A., et al. Expression of complement-regulatory proteins in normal and UW-preserved human liver. Gastroenterology 107 (1994) 505-516
15. Yamada K., Miwa T., Liu J., Nangaku M., and Song W.C. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 172 (2004) 3869-3875
16. Davitz M.A., Low M.G., and Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med 163 (1986) 1150-1161
17. Kawada M., Mizuno M., Nasu J., et al. Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. J Lab Clin Med 142 (2003) 306-312
18. Metz C.N., Brunner G., Choi-Muira N.H., et al. Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D. EMBO J 13 (1994) 1741-1751
19. Sharom F.J., and Lehto M.T. Glycosylphosphatidylinositol-anchored proteins: structure, function, and cleavage by phosphatidylinositol-specific phospholipase C. Biochem Cell Biol 80 (2002) 535-549
20. Nasu J., Mizuno M., Uesu T., et al. Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol 113 (1998) 379-385
21. Tausk F., Fey M., and Gigli I. Endocytosis and shedding of the decay accelerating factor on human polymorphonuclear cells. J Immunol 143 (1989) 3295-3302
22. Ahmad S.R., Lidington E.A., Ohta R., et al. Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition. Immunology 110 (2003) 258-268
23. Liu J., Miwa T., Hilliard B., et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201 (2005) 567-577